WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
784 Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
758 Views
WuXi Biologics: Updated Valuation Data
We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet. The updated...
700 Views
Smartkarma - ECM Coverage Weekly Update (18 Feb 2017)
Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. Accuracy Rate: Our...
176 Views
An Early Look at WuXi Biologics
WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing. The document...
846 Views